Suppr超能文献

在放化疗期间摄入生酮饮食对直肠癌患者的生活质量和代谢健康有有益影响。

Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer.

机构信息

Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Robert-Koch-Straße 10, 97422, Schweinfurt, Germany.

Darmzentrum Leopoldina Hospital, Schweinfurt, Germany.

出版信息

Eur J Nutr. 2022 Feb;61(1):69-84. doi: 10.1007/s00394-021-02615-y. Epub 2021 Jun 27.

Abstract

PURPOSE

Interest in ketogenic diets (KDs) as complementary nutritional treatments for cancer patients is rising, although some skepticism about their safety exists. We, therefore, studied the effects of KDs on quality of life and blood parameters in rectal cancer patients undergoing radio-chemotherapy.

METHODS

EORTC-QLQ30 questionnaire scores and different metabolic and hormonal blood parameters were obtained prior to, in the middle of and at the end of radiotherapy within the KETOCOMP study (ClinicalTrials.gov Identifier: NCT02516501). A total of 18 patients consuming a KD were compared to 23 patients consuming their standard diet (SD). Baseline-end differences were measured using Wilcoxon tests, and repeated measures analysis was performed using linear mixed effects models.

RESULTS

Eighty-nine percent of patients on the KD reported subjectively feeling good or very good, but roughly half of them rated the daily routine implementation as difficult. Only the SD group experienced significant declines in physical and role functioning, while the KD group improved in role (p = 0.045), emotional (p = 0.018) and social functioning (p = 0.009).Urinary frequency, buttock pain and fatigue significantly increased in the SD group, but to a much lesser extent in the KD group. Several biomarkers of metabolic health (gamma-glutamyl-transpeptidase, triglyceride-glucose index, HDL cholesterol/triglyceride ratio, and free T3) improved in the KD, but not the SD group.

CONCLUSIONS

Despite being perceived as difficult to implement by ≈50% of patients, KDs are feasible as complementary therapies alongside radio-chemotherapy and associated with subjective well-being. The hypothesis that they exert beneficial effects on quality of life and metabolic health in rectal cancer patients is supported by our data.

TRIAL REGISTRATION

ClinicalTrials.gov identifier NCT02516501, registered Aug 6th 2015.

摘要

目的

人们对生酮饮食(KDs)作为癌症患者补充营养治疗的兴趣日益增加,尽管对其安全性存在一些质疑。因此,我们研究了 KDs 对接受放化疗的直肠癌患者生活质量和血液参数的影响。

方法

在 KETOCOMP 研究中(ClinicalTrials.gov 标识符:NCT02516501),在放疗前、放疗中期和放疗结束时,我们分别使用 EORTC-QLQ30 问卷评分和不同的代谢和激素血液参数对患者进行评估。我们将 18 名接受 KD 的患者与 23 名接受标准饮食(SD)的患者进行了比较。使用 Wilcoxon 检验测量基线-终点差异,使用线性混合效应模型进行重复测量分析。

结果

89%的 KD 组患者主观上感觉良好或非常好,但大约一半的患者认为日常实施困难。只有 SD 组患者的身体和角色功能明显下降,而 KD 组患者的角色功能(p=0.045)、情绪(p=0.018)和社会功能(p=0.009)有所改善。SD 组患者的尿频率、臀部疼痛和疲劳显著增加,而 KD 组患者的增加程度要小得多。KD 组的一些代谢健康生物标志物(γ-谷氨酰转肽酶、甘油三酯-葡萄糖指数、高密度脂蛋白胆固醇/甘油三酯比值和游离 T3)有所改善,但 SD 组没有。

结论

尽管约 50%的患者认为实施 KD 困难,但作为放化疗的补充治疗,KD 是可行的,并且与主观幸福感相关。我们的数据支持 KDs 对直肠癌患者生活质量和代谢健康有益的假设。

试验注册

ClinicalTrials.gov 标识符 NCT02516501,于 2015 年 8 月 6 日注册。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验